This site is intended for Healthcare professionals.

Stopping aspirin 3 months after stenting does not increase death risk: ACC

Stopping aspirin 3 months after stenting does not increase death risk: ACC

DELHI: Aspirin has long been known to reduce the risk of stroke, heart attack, and cardiovascular disease. However, a new study presented at the American College of Cardiology’s 68th Annual Scientific Session has found that patients who did not take aspirin three months after stenting but continued taking P2Y12 inhibitor–clopidogrel, prasugrel or ticagrelor–did not experience high rates of death from any cause, stroke or heart attack. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding.

In this study, the doctors seek to determine the drug combinations offering the best complement with the latest generation of drug-eluting stents–small mesh tubes used to open blocked arteries that release drugs to prevent new blockages from forming around the stent.

After undergoing a procedure known as percutaneous coronary intervention (PCI) to insert a stent, patients can be at risk for adverse events related to clotting, including heart attack and stroke. For this reason, antiplatelet medications are used to reduce the body’s ability to clot blood, but they also raise the risk of uncontrolled bleeding.

................................ Advertisement ................................

Current guidelines recommend balancing these risks by prescribing aspirin and one of three P2Y12 inhibitors for at least 12 months when a patient receives a stent after a heart attack (or six months for patients receiving a stent for angina), a strategy known as dual antiplatelet therapy (DAPT). The new trial, known as SMART-CHOICE, assessed whether stopping aspirin after three months but continuing the P2Y12 inhibitor alone for 12 months would offer better results.

“Our study demonstrated that P2Y12 inhibitor monotherapy after a short duration of DAPT is a novel antiplatelet strategy balancing ischemic and bleeding risk in patients undergoing PCI,” said Joo-Yong Hahn, professor of medicine at Sungkyunkwan University School of Medicine in Seoul, South Korea, and the study’s lead author. “Even though this treatment strategy needs to be confirmed in other trials, aspirin may be discontinued in most patients receiving current-generation drug-eluting stents, especially in patients with bleeding risk or in those with stable ischemic heart disease.”

................................ Advertisement ................................

The trial enrolled 2,993 patients who underwent PCI and received a drug-eluting stent at 33 medical centers in South Korea. Patients were randomly assigned to receive either standard DAPT for a year or aspirin plus a P2Y12 inhibitor for three months and continue with only the P2Y12 inhibitor for nine more months after that.

Key findings of the study include:

  • After one year, 2.9 percent of patients who stopped aspirin early experienced the primary endpoint, a composite of death from any cause, heart attack or stroke, compared to 2.5 percent among those following standard DAPT. Based on thresholds determined before the trial began, these rates indicate that stopping aspirin early was not inferior to DAPT in terms of the trial’s primary endpoint.
  • Stopping aspirin early was found to reduce the risk of bleeding by about 40 percent.
  • Overall, 2 percent of those stopping aspirin experienced major bleeding compared to 3.4 percent among those following standard DAPT.
  • Taken together, the net rate of all adverse clinical events (death from any cause, heart attack, stroke or bleeding) was not significantly different between the two groups.

A little more than three-quarters of the study participants took clopidogrel, the most common P2Y12 inhibitor, with the rest taking either prasugrel or ticagrelor. Hahn said that the trial’s inclusion of different P2Y12 inhibitors distinguishes it from other trials investigating alternatives to DAPT.

“The SMART-CHOICE trial has a unique design to include all kinds of P2Y12 inhibitors, including clopidogrel, prasugrel, and ticagrelor,” Hahn said. “Therefore, we believe that the SMART-CHOICE trial, compared with several ongoing trials on P2Y12 inhibitor monotherapy after PCI, provides more generalizable answers to the concept of P2Y12 inhibitor monotherapy across a broad spectrum of patients receiving current-generation drug-eluting stents.”

The researchers will further analyze the data to determine whether the type of P2Y12 inhibitor used or variables reflecting patients’ physiological response to the P2Y12 inhibitor may affect outcomes. In addition, they are investigating whether the risk of ischemic events varied among patients with acute coronary syndrome versus stable ischemic heart disease.

Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted